Paradigm Biocapital Advisors
Paradigm Biocapital Advisors reported 30 stocks worth $5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (25.4%), GMAB (10.0%) and EWTX (8.7%). Compared with Q2 2026, the fund opened new positions in BBIO, OBX and GPCR, added to GMAB, EWTX and SYRE, trimmed RVMD, BLTE and TARS and sold out of ALNY, EYPT and MPLT.
Latest filing: what Paradigm Biocapital Advisors did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() RVMD Revolution Medicines Inc | $1.3B | 25.4% | 6.2M | −142K (−2%) | 8 of 8 | |
| 2 | ![]() GMAB Genmab A/s | $504M | 10.0% | 14.1M | +1M (+8%) | 5 of 8 | |
| 3 | ![]() EWTX Edgewise Therapeutics Inc | $438M | 8.7% | 10.8M | +563K (+6%) | 8 of 8 | |
| 4 | ![]() SYRE Spyre Therapeutics Inc | $397M | 7.9% | 4.5M | +617K (+16%) | 8 of 8 | |
| 5 | ![]() INSM Insmed Inc | $308M | 6.1% | 2.7M | +1.4M (+103%) | 4 of 8 | |
| 6 | ![]() MBX Mbx Biosciences Inc | $221M | 4.4% | 3.8M | +1.3M (+50%) | 2 of 8 | |
| 7 | ![]() ORKA Oruka Therapeutics Inc | $208M | 4.1% | 2.5M | +349K (+16%) | 5 of 8 | |
| 8 | ![]() BLTE Belite Bio Inc | $194M | 3.9% | 1.1M | −91K (−7%) | 3 of 8 | |
| 9 | ![]() TARS Tarsus Pharmaceuticals Inc | $181M | 3.6% | 2.3M | −474K (−17%) | 8 of 8 | |
| 10 | ![]() TNGX Tango Therapeutics Inc | $174M | 3.5% | 7M | +604K (+10%) | 4 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
NUVALENT INC | $732M | 5.9M |
APOGEE THERAPEUTICS INC | $209M | 1.6M |
![]() ALNY Alnylam Pharmaceuticals Inc | $144M | 480K |
![]() EYPT Eyepoint Pharmaceuticals Inc | $41.3M | 2.9M |
![]() MPLT Maplight Therapeutics Inc | $24.6M | 686K |
🔒 Free account: see all 6.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Paradigm Biocapital Advisors 13F FAQ
What does Paradigm Biocapital Advisors own?
Paradigm Biocapital Advisors reported 30 stocks worth $5B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are RVMD (25.4%), GMAB (10.0%) and EWTX (8.7%). The table above lists every position in the filing (the top 10 without an account).
What did Paradigm Biocapital Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 8 new positions, 13 added to, 6 trimmed and 6 sold out. New positions include BBIO, OBX and GPCR. It sold all of ALNY, EYPT and MPLT.
When will Paradigm Biocapital Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Paradigm Biocapital Advisors's portfolio worth?
The Q3 2026 filing reports $5B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.





















